The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Aug. 16, 2022

Filed:

Jun. 13, 2019
Applicant:

Astrazeneca Uk Limited, Cambridge, GB;

Inventors:

Richard L. Skelly, Flourtown, PA (US);

Judy Firor, Landenberg, PA (US);

Assignee:

ASTRAZENECA UK LIMITED, Cambridge, GB;

Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
G16H 10/20 (2018.01); G16H 10/40 (2018.01); G16H 10/60 (2018.01); G16H 70/40 (2018.01); G16H 20/10 (2018.01); G16H 15/00 (2018.01); A61K 31/4422 (2006.01);
U.S. Cl.
CPC ...
G16H 10/20 (2018.01); G16H 10/40 (2018.01); G16H 10/60 (2018.01); G16H 20/10 (2018.01); G16H 70/40 (2018.01); A61K 31/4422 (2013.01); G16H 15/00 (2018.01);
Abstract

A method is provided for lowering blood pressure in a subject in need thereof by administering a dihydropyridine-type calcium channel blocker pharmaceutical composition to a subject qualified for over-the-counter access to the dihydropyridine-type calcium channel blocker pharmaceutical composition. In some embodiments, the dihydropyridine-type calcium channel blocker pharmaceutical composition includes isradipine, nifedipine, or nisoldipine. In some embodiments, the dihydropyridine-type calcium channel blocker pharmaceutical composition includes 3-O-ethyl 5-O-methyl 2-(2-aminoethoxymethyl)-4-(2-chlorophenyl)-6-methyl-1,4-dihydropyridine-3,5-dicarboxylate or a pharmaceutically acceptable salt thereof.


Find Patent Forward Citations

Loading…